Mechanism of action and metabolic effects of exenatide in obesity

Trial Profile

Mechanism of action and metabolic effects of exenatide in obesity

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results assessing the effect of exenatide on glucose disposal, beta cell function and incretin hormones in non-diabetic obese subjects, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 25 Jun 2013 Status changed from recruiting to completed, according to presentation of results at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top